Chemical Technology

Validation of Titration Methods

September 8, 2022

Validation of Titration
The quality of your product depends on the analyses performed in quality control. That is why you rely on
first-rate analytical instruments for the most accurate and precise results, and product quality

Spotlight

Cellectis

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 17 years of expertise in gene editing built on its flagship TALEN® technology and pioneering electroporation system PulseAgile Cellectis uses the power of the immune system to target and eradicate cancer cells. Using its life-science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market.

OTHER WHITEPAPERS
news image

EXPLORING RESEARCH TRENDS IN CARBON DIOXIDE SEQUESTRATION

whitePaper | May 12, 2022

Carbon dioxide (CO2) is a critical component for plant life and consequently all animal and human life on Earth. However, CO2 accounts for the bulk of atmospheric greenhouse gases and these gases trap solar radiation in Earth’s atmosphere, resulting in global warming. S

Read More
news image

2020 oil, gas, and chemical industry outlook

whitePaper | February 26, 2020

As we, once again, move from one year to the next, how do we assess the oil and gas and chemical sectors’ performance in 2019 and its prospects for 2020? As always, there are headwinds and tailwinds, risks and opportunities, uncertainties and foreseeable trends, but in this report we aim to take stock of the main factors to watch for in 2020 across the diverse oil, gas, and chemical industry.

Read More
news image

Addressing decarbonization at the grid edge

whitePaper | December 24, 2022

This whitepaper discusses decarbonization and how it affects consumers in the commercial and industrial (C&I) sector. It is based on expert insight and market interviews conducted during summer of 2020 and reflects Siemens’ and Delta-EE’s common view on the topic.

Read More
news image

chemicals Evolution of a digital twin with an ethylene plant as an example

whitePaper | January 17, 2020

A digital twin of a process plant as an integrated concept covers three core points: The digital twin of the product, the digital twin of the production plant and the digital modeling of the performance of the product and production. The functional scope of a digital twin essentially depends on its purpose. In the process industry, this can be everything from the safety analysis, product simulation or the optimization of the production process, right up to economic benefit formulation.

Read More
news image

Lithium batteries whitepaper

whitePaper | December 25, 2022

Founded in 1903, Brookes Bell is a leading multi-disciplinary technical and scientific consultancy serving the marine and energy sectors. We investigate, troubleshoot and advise on a broad range of marine and energy matters and enjoy a reputation.

Read More
news image

CHEMICAL INHIBITORS TO RAS ONCOPROTEINS:CURRENT LANDSCAPE AND FUTURE OPPORTUNITIES

whitePaper | June 21, 2022

RAS is the most frequently mutated gene family in human cancers that have been considered “undruggable” due to the elusive nature of RAS inhibitors.

Read More

Spotlight

Cellectis

Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 17 years of expertise in gene editing built on its flagship TALEN® technology and pioneering electroporation system PulseAgile Cellectis uses the power of the immune system to target and eradicate cancer cells. Using its life-science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market.

Events